Tophaceous GoutPhase 3NCT07089888
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
A Phase 3 study testing Allopurinol and Dotinurad in people with Tophaceous Gout, run by Crystalys Therapeutics at 95 sites in United States.
Trial summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Tophaceous Gout
- What is being tested?
- Allopurinol and Dotinurad
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 95 sitesUnited States
- Study dates
- 4 Aug 2025to 31 Dec 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Between 18 and 75 years of age (inclusive) at the time of signing informed consent.
- Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria for at least 1 year.
- Has ≥1 measurable tophus on the hands/wrists and/or feet/ankles between Screening and Day 1. A measurable tophus is defined as ≥5 mm and ≤30 mm in the longest diameter.
- sUA level ≥5.0 mg/dL at Screening Visit 1 (Day -35 Visit) and Screening Visit 2 (Day -7 Visit).
- Female participants of childbearing potential must have a negative serum pregnancy test at Screening Visit 1 (Day -35 Visit) and Screening Visit 2 (Day -7 Visit), a negative urine pregnancy test on Day 1, and must not be breastfeeding.
- Fertile male participants and female participants of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use acceptable contraception from the time of signing informed consent through 30 days after the last dose of study drug.
Who cannot join
- History of or presence of kidney stones within 1 year prior to Screening.
- History of or presence of malignancy in the last 5 years other than treated cutaneous basal or squamous cell carcinoma.
- Hypersensitivity or intolerance to dotinurad or to colchicine and nonsteroidal anti-inflammatory drugs (NSAIDs).
- Known or suspected history of drug abuse, a positive drug test at Screening Visit 1, or a recent history of alcohol abuse.
- Known history of or positive results for human immunodeficiency virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV) during Screening.
Trial locations and contacts
95 sites in 1 country. Contact the study team or a site near you to ask about taking part.
95 sites in 1 country
United States95 sites, 83 recruiting
- Recruiting
A. Alfred Taubman Health Care Center
Ann Arbor, Michigan, 48109
Puja Khanna, 48109
- Withdrawn
DelRicht Research - Atlanta
Atlanta, Georgia, 30329
- Recruiting
The Kirklin Clinic of University of Alabama Birmingham Hospital
Birmingham, Alabama, 35233
Kenneth Saag, MD
- Withdrawn
Alabama Clinical Therapeutics
Birmingham, Alabama, 35235
- Recruiting
Bradenton Research Center
Bradenton, Florida, 34205
Eric Folkens, MD
- Recruiting
Ellipsis Research Group
Brooklyn, New York, 11215
Jorge Serje, MD
- Recruiting
DelRicht Research
Charlotte, North Carolina, 28210
Olabisi Badmus, MD
- Recruiting
Charlottesville Medical Research
Charlottesville, Virginia, 22911
James Clark, MD
- Recruiting
Chicago Clinical Research Institute, Inc. (CCRII)
Chicago, Illinois, 60607
Manognya Sama
Dennis Levinson, MD
- Recruiting
Flourish Chicago - Ravenswood (Great Lakes Clinical Trials)
Chicago, Illinois, 60640
Manish Jain, MD
- Recruiting
Herco Medical and Research Center, Inc
Coral Gables, Florida, 33134
Eddy Capote, MD
- Recruiting
Arthritis & Osteoporosis Center of Coastal Bend
Corpus Christi, Texas, 78415
Eric Chiang, MD
- Recruiting
Medvin Clinical Research - Covina
Covina, California, 91722
Samy Metyas, MD
- Recruiting
Zenos Clinical Research
Dallas, Texas, 75230
Durga Tanneru, MD
- Recruiting
Hometown Urgent Care and Research - Dayton
Dayton, Ohio, 45424
Steve Choi, MD
- Recruiting
Pediatrics & Adult Medicine/SKYCRNG
Decatur, Georgia, 30034
Michele Sewell, MD
- Recruiting
SKYCRNG - Rophe Adult and Pediatric Medicine
Decatur, Georgia, 30034
Dwight Blake, MD
- Recruiting
Lone Star Arthritis & Rheumatology Associates - Denton
Denton, Texas, 76205
Awilda (Michelle) Luciano, MD
- Recruiting
Denver Arthritis Clinic - Lowry
Denver, Colorado, 80230
Christopher Antolini, MD
- Recruiting
Epic Medical Research - DeSoto
DeSoto, Texas, 75115
Haresh Boghara, MD
- Recruiting
West Coast Research
Dublin, California, 94568
Tim Davis
Alfred Tan, MD
- Recruiting
MediSphere Medical Research Center, LLC - East
Evansville, Indiana, 47714
Hubert Reyes, MD
- Recruiting
G & L Research
Foley, Alabama, 36535
Nidal Morrar, MD
- Recruiting
Arizona Arthritis & Rheumatology Associates (AARA) - Gilbert
Gilbert, Arizona, 85297
Daniel Kreutz, MD
- Recruiting
Arizona Arthritis & Rheumatology Associates (AARA) - Glendale
Glendale, Arizona, 85306
Nehad Soloman, MD
- Recruiting
Boeson Research - Great Falls
Great Falls, Montana, 59405
Richard Horng-Chy Lai, MD
- Recruiting
Triad Clinical Trials
Greensboro, North Carolina, 27410
Richard Montgomery, MD
- Withdrawn
DelRicht Research - Hendersonville
Hendersonville, Tennessee, 37075
- Recruiting
New Generation of Medical Research
Hialeah, Florida, 32016
Karelia Ruiz, MD
- Recruiting
Best Quality Research
Hialeah, Florida, 33016
Gustavo Ledo-Sanchez, MD
- Recruiting
Prolato Clinical Research Center
Houston, Texas, 77027
Michelle Eisenberg, MD
- Recruiting
Pioneeer Research Solutions
Houston, Texas, 77099
Mozaffari Shahin
Francisco Velazquez, MD
- Recruiting
Epic Medical Research - Hurst
Hurst, Texas, 76054
Robert Strzinek, MD
- Withdrawn
Delricht Research - Better Life Direct Primary Care
Indianapolis, Indiana, 46202
- Recruiting
Health Awareness Inc
Jupiter, Florida, 33458
Ronald Surowitz, MD
- Recruiting
R & H Clinical Research - South Fry Road
Katy, Texas, 77450
Maryam Khawari, MD
- Recruiting
Clinical Research of Center Florida
Lakeland, Florida, 33805
Michael Gimness, MD
- Recruiting
Premise Clinical Research Center
Lancaster, Texas, 75146
Josier Nisnisan, MD
- Recruiting
Alliance Clinical Lewisville (Epic Clinical Research)
Lewisville, Texas, 75057
Manjoo Sharma, MD
- Recruiting
DelRicht Research - Louisville (Derby City DPC)
Louisville, Kentucky, 40205
Michael Lovelace, MD
- Recruiting
D&H Pompano Research Center
Margate, Florida, 33063
Mazyar Rouhani, MD
- Withdrawn
Delricht Research - Concierge Medicine Of Cincinnati
Mason, Ohio, 45040
- Recruiting
Southland Arthritis and Osteoporosis Medical Center, Inc
Menifee, California, 92586
Amal Mehta, MD
- Recruiting
Arizona Arthritis & Rheumatology Associates (AARA) - Mesa
Mesa, Arizona, 85210
Swati Bharadwaj, MD
- Recruiting
Southwest Rheumatology Research
Mesquite, Texas, 75150
Atul Singhal, MD
- Active, not recruiting
Tandem Clinical Research - Metairie Clinic
Metairie, Louisiana, 70006
- Recruiting
Well Pharma Medical Research
Miami, Florida, 33173
Eddie Armas, MD
- Recruiting
Anchor Medical Research, LLC
Miami, Florida, 33176
Juvental Martinez, MD
- Recruiting
Panax Clinical Research
Miami Lakes, Florida, 33014
Robert G. Perry, MD
- Recruiting
DelRicht Research - LCMC Health Urgent Care - Lakeview
New Orleans, Louisiana, 70124
Emily Krambeck
Patrick Dennis, MD
- Recruiting
NYU Langone Health
New York, New York, 10016
Michael Pillinger, MD
- Recruiting
Infinity Clinical Research
Norco, California, 92860
Peter Mattar, MD
- Recruiting
Coastal Carolina Research Center - Main
North Charleston, South Carolina, 29405
Rica Santiago, MD
- Recruiting
Las Vegas Clinical Trials
North Las Vegas, Nevada, 89030
Alton Walters, MD
- Recruiting
Amicis Research Center - Balboa
Northridge, California, 91324
Pascal Dabel, MD
- Recruiting
Gateway Clinical Trials
O'Fallon, Illinois, 62269
Christopher Anderson, MD
- Recruiting
Ogden Clinic Canyon View/RIO Clinical Trials
Ogden, Utah, 84404
Stephen Bruce, MD
- Recruiting
Curalta Clinical Trials
Oradell, New Jersey, 07649
Vincent Giacalone, MD
- Recruiting
Cure Clinical Research, LLC
Orange, California, 92866
Ramprasad (Ram) Dandillaya, MD
- Recruiting
Omega Research DeBary
Orlando, Florida, 32808
Kwabena Ayesu, MD
- Recruiting
Delricht Research - Concierge And Direct Primary Care
Overland Park, Kansas, 66223
Jonathan T. Jacobs, MD
- Recruiting
MD Medical Research - Oxon Hill
Oxon Hill, Maryland, 20745
Stephen Ong, MD
- Withdrawn
Dream Team Clinical Research
Pomona, California, 91767
- Recruiting
DelRicht Research - Prairieville
Prairieville, Louisiana, 70769
Brittany Bolton
Taylor Sanders, MD
- Recruiting
Health Concepts
Rapid City, South Dakota, 57702
Richard Beasley, MD
- Withdrawn
DelRicht Research - Maryland (Matthew L. Mintz, MD, FACP)
Rockville, Maryland, 20852
- Recruiting
Clinical Research Institute of Michigan - St. Clair Shores
Saint Clair Shores, Michigan, 48081
Amar Majjhoo, MD
- Recruiting
Discovery Clinical Trials
San Antonio, Texas, 78229
Abha Gyani, MD
- Recruiting
ERG - Endeavor Clinical Trials
San Antonio, Texas, 78240
Nitendra Agarwal, MD
- Recruiting
Velocity Clinical Research - San Bernardino
San Bernardino, California, 92408
Diana Albay, MD
- Recruiting
Acclaim Clinical Research, Inc.
San Diego, California, 92120
Julie Vu, MD
- Recruiting
East Bay Rheumatology Medical Group
San Leandro, California, 94578
Suneet Grewal, MD
- Recruiting
Epic Medical Research - San Marcos
San Marcos, Texas, 78666
Maria Salinas, MD
- Recruiting
Shelby Clinical Research, LLC - North Carolina
Shelby, North Carolina, 28150
Christian Martin, MD
- Withdrawn
DM Clinical Research - Detroit
Southfield, Michigan, 48076
- Recruiting
Premier Health Research
Sparta, New Jersey, 07871
Haroon Sarwar, MD
- Recruiting
BTC Network - Encompass Clinical Research
Spring Valley, California, 91978
Hanid Audish, MD
- Withdrawn
Delricht Research - Command Family Medicine
Springfield, Missouri, 65807
- Recruiting
Revival Research Institute - Sterling Heights
Sterling Heights, Michigan, 48313
Syed Husain, MD
- Recruiting
Siena Research Network
Sugar Land, Texas, 77479
Mehjabin Parkar, MD
- Recruiting
Clinical Research Trials of Florida
Tampa, Florida, 33607
Viviana Fonseca
Sady Alpizar, MD
- Recruiting
Cohen Medical Centers
Thousand Oaks, California, 91360-3967
Shariar Cohen-Gadol, MD
- Recruiting
DM Clinical Research - Tomball - Multiple Specialties
Tomball, Texas, 77375
Shaikh Ali, MD
- Recruiting
DelRicht Research - Town and Country
Town and Country, Missouri, 63017
Amy E. Roberts, MD
- Recruiting
Oakland Medical Center
Troy, Michigan, 48085
Jay Sandberg, MD
- Recruiting
Del Sol Research Management - Tucson East
Tucson, Arizona, 85715
Vicki Kalen, MD
- Recruiting
Medvin Clinical Research - Tujunga
Tujunga, California, 91042
Dan La, MD
- Withdrawn
DelRicht Research - Tulsa
Tulsa, Oklahoma, 74133
- Recruiting
Preferred Primary Care Physicians - Matthew Drive
Uniontown, Pennsylvania, 15401
Christopher Labuda, MD
- Recruiting
Gershon Pain Specialists
Virginia Beach, Virginia, 23454
Steven Gershon, MD
- Recruiting
MedVadis Research
Waltham, Massachusetts, 02451
David DiBenedetto, MD
- Withdrawn
Suburban Research Associates - West Chester Office
West Chester, Pennsylvania, 19380
- Recruiting
Sahni Rheumatology & Therapy
West Long Branch, New Jersey, 07764
Kiren Sahni, MD
- Recruiting
Digestive Health Research of North Texas
Wichita Falls, Texas, 76301
Vanya Wagler, MD
- Recruiting
Conquest Research - Winter Park
Winter Park, Florida, 32789
Anand Patel, MD
About this study
Official title: A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Tophaceous Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
- Conditions
- Tophaceous Gout
- Being tested
- Allopurinol, Dotinurad
- Keywords
- Tophaceous Gout, Dotinurad, Allopurinol, Hyperuricemia
- Medical subject headings
- Hyperuricemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AllopurinolDrug
Over-encapsulated tablets containing active drug substance administered orally (PO).
DotinuradDrug
Over-encapsulated tablets containing active drug substance administered PO.
| Study group | Role | What they receive |
|---|---|---|
| Allopurinol | Active comparator | Participants will discontinue their allopurinol and start on study-supplied allopurinol at the same dose once a day (QD) through Week 76. Receives: Drug: Allopurinol |
| Dotinurad | Experimental | Participants will discontinue their allopurinol and start dotinurad 1 mg QD for first 4 weeks (Weeks 1-4), dotinurad 2 mg QD for the next 8 weeks (Weeks 5-12), and dotinurad 4 mg QD thereafter up through Week 76. Receives: Drug: Dotinurad |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24
Measured: Week 24
Secondary outcomes (16)
Percentage of Participants who Experience Complete Response (CR) or Partial Response (PR) of ≥1 Target Tophus at Week 76
Measured: Week 76
Percentage of Participants who Experience CR of ≥1 Target Tophus at Week 76
Measured: Week 76
Percentage of Participants with an sUA Level <4.0 mg/dL at Week 24
Measured: Week 24
Mean Rate of Gout Flares Requiring Treatment from Week 36 Through Week 76
Measured: Week 36 through Week 76
Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 and No Gout Flares Requiring Treatment from Week 36 Through Week 76
Measured: Week 24 and Week 36 through Week 76
Mean Change from Baseline in sUA at Week 24
Measured: Baseline and Week 24
Mean Percent Change from Baseline in the Sum of the Areas for all Target Tophi at Each Visit
Measured: Baseline to Week 80
Percentage of Participants who Do Not have a Gout Flare Requiring Treatment from Week 36 through Week 76
Measured: Week 36 through Week 76
Percentage of Participants with an sUA Level <5.0 mg/dL at Each Visit
Measured: Up to Week 80
Percentage of Participants with an sUA Level <4.0 mg/dL at Each Visit
Measured: Up to Week 80
Percentage of Participants with an sUA Level <3.0 mg/dL at Each Visit
Measured: Up to Week 80
Absolute Change from Baseline in sUA Levels at Each Visit
Measured: Baseline to Week 80
Percent Change from Baseline in sUA Levels at Each Visit
Measured: Baseline to Week 80
Percentage of Participants with a Gout Flare Requiring Treatment at Each Month Between Week 24 and the End of Study
Measured: Week 24 to Week 80
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Measured: Up to Week 80
Percentage of Participants with Serious Adverse Events (SAEs)
Measured: Up to Week 80
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2025
- Study start4 Aug 2025
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tophaceous GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Crystalys Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07089888
- Sponsor's protocol ID
- FYU-981-CRYS-302
- Other IDs
- 2024-520207-84-00
- Status last verified
- Sep 2026
- First submitted
- 22 Jul 2025
- Last updated
- 28 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported for publication, after deidentification.